Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator
The summary for the Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the Assistant Secretary for Preparedness and Response, which is the U.S. government agency offering this grant.
Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator: The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products.
BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates.
BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates.
Federal Grant Title: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
Federal Agency Name: | Assistant Secretary for Preparedness and Response |
Grant Categories: | Science and Technology |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | EP-IDS-16-001 |
Type of Funding: | Cooperative Agreement |
CFDA Numbers: | 93.360 |
CFDA Descriptions: | Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development |
Current Application Deadline: | Apr 15, 2016 Applications must be submitted elect |
Original Application Deadline: | Apr 15, 2016 Applications must be submitted elect |
Posted Date: | Feb 17, 2016 |
Creation Date: | Feb 18, 2016 |
Archive Date: | May 15, 2016 |
Total Program Funding: | $250,000,000 |
Maximum Federal Grant Award: | $30,000,000 |
Minimum Federal Grant Award: | $30,000,000 |
Expected Number of Awards: | 1 |
Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- Public and State controlled institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Small businesses - Additional Information on Eligibility
- Research institutions and Non-domestic (non-U.S.) entities are eligible.
- Link to Full Grant Announcement
- Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator
- Grant Announcement Contact
- Grants.gov Contact Center
Phone Number: 1-800-518-4726
Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays.
[email protected]
Grants.gov Customer Support
Assistant Secretary for Preparedness and Response 202-245-0961 - Similar Government Grants
- • PRI Bilateral US-Israeli
- • 2019 BARDA Division of Research, Innovation and Ventures (BARDA DRIVe) Accelerator Network...
- • QUICKFIRE
- • BARDA Division of Research, Innovation and Ventures (DRIVe) Accelerator Network
- • Office of Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Anno...
- • Opportunity EP-IDS-10-002
- • Opportunity EP-IDS-10-003
- • Development of Sustainable Influenza Vaccine Production Capacity in Under Resourced Nation...
- More Grants from the Assistant Secretary for Preparedness and Response
- • Medical Reserve Corps Small Grant Program
- • MRC STTRONG
- • PRI Bilateral US-Israeli
- • Pediatric Disaster Care
- • Military- Civilian Partnership for Trauma Readiness Grant Program